In-Line Diagnostics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Raises $20 mil. in private equity financing. The Salt Lake City firm makes Crit-Line monitors to non-invasively measure hematocrit, oxygen saturation and changes in blood volume. The funds "will allow the company to expand its renal care operations and accelerate development of its other proprietary non-invasive technologies across a variety of medical specialties and applications," states Chairman Robert Steuer. The firm simultaneously announces Aug. 11 FDA 510(k) clearance of its Crit-Scan transcutaneous hematocrit monitoring device. The Crit-Scan is "the first non-invasive device used to measure whole blood hematocrit," the firm claims, and "virtually eliminates the need for finger sticks associated with blood tests and blood donation"